Journal of Magnetic Resonance Imaging · 2024 · 10 citations · 22 references
MedicineRadiologyUrologyBiomedical ImagingDiagnostic ImagingDiagnostic RadiologyImaging BiomarkersMagnetic Resonance ImagingProstate BiopsyProstate CancerProstate HealthProstate ImagingEcho Planar ImagingInitial BiopsyProstate Health IndexProstate-specific Antigen DensitySystematic BiopsySystematic Prostate BiopsyT2-weighted ImagingTargeted Prostate Biopsy
BACKGROUND: Category 3 lesions in PI-RADSv2.1 pose diagnostic challenges, complicating biopsy decisions. Recent biomarkers like prostate health index (PHI) have shown higher specificity in detecting clinically significant prostate cancer (csPCa) than prostate-specific antigen (PSA). Yet their integration with MRI remains understudied. PURPOSE: To evaluate the utility of PSA and PHI with its derivatives for detecting csPCa in biopsy-naïve patients with category 3 lesion on initial prostate MRI scan. STUDY TYPE: Retrospective. POPULATION: One hundred ninety-three biopsy-naïve patients who underwent MRI, PSA, and PHI testing, followed by both targeted and systematic biopsies. FIELD STRENGTH/SEQUENCE: Turbo spin-echo T2-weighted imaging, diffusion-weighted single-shot echo-planar imaging, and dynamic contrast-enhanced T1-weighted fast field echo sequence imaging in 3 T. ASSESSMENT: PHI density (PHID) and PSA density (PSAD) derived by dividing serum PHI and PSA with prostate volume (MRI based methodology suggested by PI-RADSv2.1). Risk-stratified models to evaluate the utility of markers in triaging patients for biopsy, including low-, intermediate-, and high-risk groups. STATISTICAL TESTS: Independent t-test, Mann-Whitney U test, Mantel-Haenszel test, generalized estimating equation, and receiver operating characteristic (ROC) curve analysis were used. Statistical significance defined as P < 0.05. RESULTS: CsPCa was found in 16.6% (32/193) of patients. PHID had the highest area under the ROC curve (AUROC) of 0.793, followed by PHI of 0.752, PSAD of 0.750, and PSA of 0.654. PHID with two cut-off points (0.88/mL and 1.82/mL) showed the highest potential biopsy avoidance of 47.7% (92/193) with 5% missing csPCa, and the lowest intermediate-risk group (borderline decision group) at 38.9% (75/193), compared to PSA and PHI. DATA CONCLUSION: PHID demonstrated better potential in triaging patients with category 3 lesions, possibly aiding more selective and confident biopsy decisions for csPCa detection, than traditional markers. EVIDENCE LEVEL: 4 TECHNICAL EFFICACY: Stage 5.
22
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke et al. · European Urology · 2015 · 2.9K citations
ESUR prostate MR guidelines 2012
Jelle O. Barentsz, Jonathan Richenberg, R. Clements et al. · European Radiology · 2012 · 2.4K citations · Full text
Geert J.L.H. van Leenders, Theodorus van der Kwast, David J. Grignon et al. · The American Journal of Surgical Pathology · 2020 · 685 citations · Full text
Le Wang, Bin Lu, Mengjie He et al. · Frontiers in Public Health · 2022 · 643 citations · Full text